Constructing a database of individual clinical trials for longitudinal analysis

Controlled Clinical Trials

Volumn 24, Issue 3, 2003, Pages 324-340

  Schmid, Christopher H ^a   Landa, Marcia ^a   Jafar, Tazeen H ^b   Giatras, Ioannis ^c   Karim, Tauqeer ^a   Reddy, Manoj ^a   Stark, Paul C ^a   Levey, Andrew S ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^c HYGEIA HOSPITAL   (Greece)

Author keywords

ACE inhibitors; Combining information; Heterogeneity; Individual patient meta analysis; Meta analysis; Meta regression; Renal disease

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COMPUTER PROGRAM; DATA ANALYSIS; DATA BASE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FOLLOW UP; HUMAN; KIDNEY DISEASE; LANGUAGE; LONGITUDINAL STUDY; PROTEIN URINE LEVEL; TREATMENT OUTCOME;

EID: 0037693139     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(02)00319-7     Document Type: Article

References (34)

1. Schmid C.H. Exploring heterogeneity in randomized trials via meta-analysis. Drug Inf J. 3:1999;211-224.
2. Thompson S.G., Sharp S.J. Explaining heterogeneity in meta-analysis. a comparison of methods Stat Med. 18:1999;2693-2708.
3. Lambert P.C., Sutton A.J., Abrams K.R., Jones D.R. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol. 55:2002;86-94.
4. Fibrinolytic Therapy Trialists', (FTT) Collaborative Group Indications for fibrinolytic therapy in suspected acute myocardial infarction. collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients Lancet. 343:1994;311-322.
5. Stewart L.A., Clarke M.J. Practical methodology of meta-analyses (overviews) using updated individual patient data. Stat Med. 14:1995;2057-2079.
6. Selker H.P., Griffith J.L., Beshansky J.R.et al. The thrombolytic predictive instrument project. combining clinical study data bases to take medical effectiveness research to the streets Grady M.L., Schwartz H.A. Medical Effectiveness Research Data Methods. Pub. AHCPR92-0056. 1992;Agency for Health Care Policy and Research, Department of Health and Human Services, Washington DC.
7. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 339:1992;1-15. 71-85.
8. Chalmers I. The Cochrane collaboration. preparing, maintaining, and disseminating systematic reviews of the effects of health care Ann N Y Acad Sci. 703:1993;156-163.
9. Duchateau L., Pignon J.P., Bijnens L.et al. Individual patient- versus literature-based meta-analysis of survival data. time to event and event rate at a particular time can make a difference, an example based on head and neck cancer Control Clin Trials. 22:2001;538-547.
10. Jeng G.T., Scott J.R., Burmeister L.F. A comparison of meta-analytic results using literature vs. individual patient data. JAMA. 274:1995;830-836.
11. Selker H.P., Griffith J.L., Beshansky J.R.et al. Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use. A Thrombolytic Predictive Instrument Ann Intern Med. 127:1997;538-556.
12. Olkin I. Statistical and theoretical considerations in meta-analysis. J Clin Epidemiol. 48:1995;133-146.
13. Peto R., Collins R., Gray R. Large-scale randomized evidence. large, simple trials and overviews of trials J Clin Epidemiol. 48:1995;23-40.
14. Jafar TH, Schmid CH, Landa M, et al. for the AIPRD Study Group. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.
15. Jafar TH, Stark PC, Schmid CH, et al. for the AIPRD Study Group. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-1140.
16. United States Renal Data System 2001 Annual Report of the U.S. Renal Data System. 2001;National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
17. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease. evaluation, classification and stratification Am J Kidney Dis. 39:2002;S1-S266.
18. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of patient level data. Ann Intern Med. 134:2001;370-379.
19. Giatras I., Lau J., Levey A.S. Effect of angiotensin-converting-enzyme inhibitors on the progression of nondiabetic renal disease. a meta-analysis of randomized trials Ann Intern Med. 127:1997;337-345.
20. Brenner B.M., Meyer T.W., Hostetter T.H. Dietary protein intake and the progressive nature of kidney disease. the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease N Engl J Med. 307:1982;652-659.
21. Remuzzi G., Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int. 38:1990;384-394.
22. Zucchelli P., Zuccala A., Borghi M.et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 42:1992;452-458.
23. Kamper A.L., Strandgarrd S., Leyssac P.P. Effect of enalapril on the progression of chronic renal failure. Am J Hypertens. 5:1992;423-430.
24. van Essen G.G., Apperloo A.J., Rensma P.L.et al. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl. 63:1997;S58-S62.
25. Hannedouche T., Landais P., Goldfarb B.et al. Randomized controlled clinical trial of enalapril and beta-blockers in non-diabetic chronic renal failure. BMJ. 309:1994;833-837.
26. Bannister K.M., Weaver A., Clarkson A.R., Woodroffe A.J. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. In. Clarkson AR, Woodroffe AJ, editors Contrib Nephrol. 111:1995;184-192.
27. Himmelmann A., Hansson L., Hansson B.G.et al. ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Press. 4:1995;85-90.
28. Ihle B.U., Whitworth J.A., Shahinfar S., Cnaan A., Kincaid-Smith P.S. Angiotensin-converting-enzyme inhibition in non-diabetic progressive renal insufficiency. a controlled double-blind trial Am J Kidney Dis. 27:1996;489-495.
29. Maschio G., Alberti D., Janin G.et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 334:1996;939-945. and the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
30. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 349:1997;1857-1863.
31. Ruggenenti P., Perna A., Gherardi G.et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 354:1999;359-364.
32. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41.
33. White I.R., Pocock S.J. Statistical reporting of clinical trials with individual changes from allocated treatment. Stat Med. 15:1996;249-262.
34. Begg C., Cho M., Eastwood S.et al. Improving the quality of reporting of randomized controlled trials. the CONSORT statement JAMA. 276:1996;637-639.